Eurofins Scientific SE: Transplant Genomics announces launch of Trugraf® Liver, the first and only non-invasive gene expression diagnostic test to optimise immunosuppression in liver transplant recipients
September 30 2022 - 12:30AM
Business Wire
Novel diagnostic test utilises gene
expression biomarkers to confirm immune quiescence and rule out
organ rejection
Regulatory News:
Eurofins (Paris:ERF):
Transplant Genomics (“TGI”), the transplant rejection
diagnostics company committed to improving organ transplant
outcomes worldwide which is part of the Eurofins network of
companies, is pleased to announce the commercial availability of
TruGraf® Liver, a blood-based gene expression test that provides
guidance for optimisation of immunosuppression therapy in liver
transplant recipients. For liver transplant recipients, TruGraf®
Liver represents the first diagnostic tool that leverages gene
expression data—powered by TGI’s proprietary technology and machine
learning—to give the earliest and most accurate view of immune
quiescence.
Immunosuppressive medication is essential to help prevent organ
rejection following liver transplantation. Due to the significant
complications associated with the use of immunosuppression,
clinicians can choose to reduce immunosuppression for liver
transplant recipients to minimise these complications. Until now,
immunosuppression optimisation has largely been a “trial and error”
process, with clinicians relying only on laboratory and clinical
indicators of rejection and graft injury, resulting from the
effects of immune activation.
TruGraf® Liver is the first and only blood-based test that
offers biomarker guidance to aid physicians in optimising
immunosuppression in transplant recipients, to allow for a superior
balance between graft rejection and adverse events. TruGraf® Liver
can help clinicians confirm immune quiescence during
immunosuppression optimisation in patients with stable graft
function, minimising the risk of overt graft injury due to
rejection.
Josh Levitsky, MD, MS, Professor of Medicine and Surgery in the
Division of Gastroenterology and Hepatology, Northwestern
University Feinberg School of Medicine, Chicago, Illinois, detailed
the development of TruGraf® Liver in his May 2022 article in
Transplantation (https://pubmed.ncbi.nlm.nih.gov/34342962). This
study is based on findings from an NIH-funded, multi-center
longitudinal study (CTOT-14: NCT01672164) that has set the stage
for the use of non-invasive biomarkers for serial monitoring of
liver transplant recipients.
Hepatologists and other liver transplant care professionals may
learn more about TruGraf® Liver at
www.transplantgenomics.com/trugraf-liver.
About Transplant Genomics, Inc.
Transplant Genomics, Inc. (“TGI”) is a personalised diagnostics
company committed to improving organ transplant outcomes worldwide
through innovative tests that detect early signs of graft injury,
differentiate among actionable causes, and enable the optimisation
of therapy. Working alongside the transplant community and within
the Eurofins family, TGI is commercialising a suite of tests
enabling diagnoses and prediction of transplant recipient immune
status. TGI was acquired by the Eurofins Group in 2019.
Learn more about Transplant Genomics at
http://www.transplantgenomics.com.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in
food, environment, pharmaceutical and cosmetic product testing, and
in discovery pharmacology, forensics, advanced material sciences
and agroscience Contract Research services. Eurofins is also a
market leader in certain testing and laboratory services for
genomics, and in the support of clinical studies, as well as in
BioPharma Contract Development and Manufacturing. The Group also
has a rapidly developing presence in highly specialised and
molecular clinical diagnostic testing and in-vitro diagnostic
products.
With over 61,000 staff across a decentralised and
entrepreneurial network of 940 laboratories in 59 countries,
Eurofins offers a portfolio of over 200,000 analytical methods to
evaluate the safety, identity, composition, authenticity, origin,
traceability and purity of a wide range of products, as well as
providing innovative clinical diagnostic testing services and
in-vitro diagnostic products.
The Group’s objective is to provide its customers with
high-quality services, innovative solutions and accurate results on
time. Eurofins is ideally positioned to support its clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
requirements of healthcare practitioners around the world.
In 2020 and 2021, Eurofins reacted quickly to meet the global
challenge of COVID-19, by creating the capacity to help over 20
million patients monthly who may have been impacted by the pandemic
with our testing products and our services and directly supporting
healthcare professionals working on the front line to fight the
virus. The Group has established widespread PCR testing
capabilities and has carried out over 40 million tests in its own
laboratories, is supporting the development of a number of vaccines
and has established its SAFER@WORK™ testing, monitoring and
consulting programmes to help ensure safer environments, travel and
events during COVID-19.
Eurofins has grown very strongly since its inception and its
strategy is to continue expanding its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws
on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical
solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220929005395/en/
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Oct 2023 to Oct 2024